Plus Therapeutics Inc
PSTV - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$26.21M
Close$
$-0.00
100.1% downside
Current Fair Value
100.1% downsideOvervalued by 100.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $26.21 Million |
|---|---|
| Enterprise Value | $23.89 Million |
| Earnings per Share | $-7.19 |
| Beta | 1.4 |
| Outstanding Shares | 6,773,125 |
Return
| Return on Equity | -477.54% |
|---|---|
| Return on Assets | -185.94% |
| Return on Invested Capital | 366.70% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | -3.87 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -4.9 |
| Enterprise Value to EBIT | 1.19 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-0.79
Consensus analyst estimateRevenue Estimate
$1.24 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 9.76%▲ 4.26% |
|---|---|
| Total Invested | $2.89M▲ 94.12% |
| Investors Holding | 230% |
About Plus Therapeutics Inc
2,018 employees
CEO: Marc Hedrick
Plus Therapeutics is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique na...